Terms: = Leukemia AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
179 results:
1. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
[TBL] [Abstract] [Full Text] [Related]
2. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Manos K; Chong G; Keane C; Lee ST; Smith C; Churilov L; McKendrick J; Renwick W; Blombery P; Burgess M; Nelson NE; Fancourt T; Hawking J; Lin W; Scott AM; Barraclough A; Wight J; Grigg A; Fong CY; Hawkes EA
Leukemia; 2023 May; 37(5):1092-1102. PubMed ID: 36906715
[TBL] [Abstract] [Full Text] [Related]
3. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic leukemia.
Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
[TBL] [Abstract] [Full Text] [Related]
4. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract] [Full Text] [Related]
5. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid leukemia and B-Acute Lymphoblastic leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract] [Full Text] [Related]
6. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute leukemia and Thrombomodulin Alfa treatment-A Cohort Study Using a Postmarketing Surveillance Database.
Yoshinobu S; Honda G; Kawano N; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Takayuki I; Wada H
Clin Appl Thromb Hemost; 2021; 27():10760296211054094. PubMed ID: 34870471
[TBL] [Abstract] [Full Text] [Related]
8. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract] [Full Text] [Related]
9. Recognition of acute lymphoblastic leukemia and lymphocytes cell subtypes in microscopic images using random forest classifier.
Mirmohammadi P; Ameri M; Shalbaf A
Phys Eng Sci Med; 2021 Jun; 44(2):433-441. PubMed ID: 33751420
[TBL] [Abstract] [Full Text] [Related]
10. Diagnosis and surgical treatment of primary isolated aggressive lumbar myeloid sarcoma: a rare case report and review of the literatures.
Bai CR; Li X; Wang JS; Li JJ; Liu N; Fei Q; Li D; Yang Y
BMC Musculoskelet Disord; 2021 Feb; 22(1):220. PubMed ID: 33627110
[TBL] [Abstract] [Full Text] [Related]
11. Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
Kobayashi T; Ubukawa K; Fujishima M; Takahashi N
Int J Hematol; 2021 Apr; 113(4):600-605. PubMed ID: 33387296
[TBL] [Abstract] [Full Text] [Related]
12. Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature.
Berti PP; Pirillo V; Rizzo P; Ria A; Mannelli F; Broger M
Br J Neurosurg; 2023 Oct; 37(5):1266-1268. PubMed ID: 33249871
[TBL] [Abstract] [Full Text] [Related]
13. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
[TBL] [Abstract] [Full Text] [Related]
14. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
Harker-Murray PD; Pommert L; Barth MJ
J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
[TBL] [Abstract] [Full Text] [Related]
15. Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study.
Kakaje A; Alhalabi MM; Ghareeb A; Karam B; Mansour B; Zahra B; Hamdan O
Sci Rep; 2020 Apr; 10(1):6756. PubMed ID: 32317670
[TBL] [Abstract] [Full Text] [Related]
16. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract] [Full Text] [Related]
17. Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.
Moshofsky KB; Cho HJ; Wu G; Romine KA; Newman MT; Kosaka Y; McWeeney SK; Lind EF
Blood Adv; 2019 Oct; 3(20):3038-3051. PubMed ID: 31648326
[TBL] [Abstract] [Full Text] [Related]
18. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
[TBL] [Abstract] [Full Text] [Related]
19. Agressive NK-cell leukemia in a pediatric patient.
Rey-Helo E; Pérez-Velásquez RD; Cortés-Alva D
Bol Med Hosp Infant Mex; 2019; 76(4):188-192. PubMed ID: 31303650
[TBL] [Abstract] [Full Text] [Related]
20. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract] [Full Text] [Related]
[Next]
